Clinical Trial Search

Primary: Number of Participants With at Least 1 Clinically Relevant and Objectively Confirmed Thrombovascular Event From Randomization Through Week 16 — 5; 10 particpants — p=0.248

Primary: Hematopoietic Response Rate Defined as the Number of Participants Who Exhibit a Hematopoietic Response — 114; 109; 106; 50 Participants — p=0.39

Primary: The Percentage of Participants Who Exhibit a Hematopoietic Response — 68.9; 61.7; 65.5; 66.7 Percentage of participants — p=>0.41

Primary: Efficacy of HX575 in the Treatment of Chemotherapy Associated Anemia — 37; 15 Participants

Primary: Percentage of Participants With Response to Treatment — 50.8 percentage of participants

Primary: Percentage of Participants With Febrile Neutropenia (FN) — 8; 8; 15; 9 percentage of participants

Primary: The Median Hb Change From Baseline to Week 12 — 2.35; 1.5; 0.5 gm/dl

Primary: Number of Participants Who Achieved the Target Hemoglobin Level, by Darbepoetin Alfa Dose — 71; 82 Participants

Primary: Maximum Change in Hb Within 16 Weeks From Baseline Without Red Blood Cell (RBC) Transfusion — 2.47 g/dL

Primary: Percentage of Participants With a Decrease in Hemoglobin ≥ 0.5 g/dL From Week 3 to Week 18 — 42; 60 Participants — p=0.0143

Primary: Change From Baseline to the Maximum Hemoglobin Level During Stage 2 (Week 9 Through Week 21). — 2.6; 1.8; 2.5; 1.3 g/dL

Primary: Percentage of Participants Receiving Darbepoetin Alfa With Improvement in Patient Perceived Fatigue (PPF) and Increase in Hemoglobin ≥ 1 g/dL — 31.8 percentage of…

Primary: Change From Baseline in Hemoglobin at Day 28 — 1.3 g/dL

Primary: Number of Participants With Clinically Significant Events — 4; 3; 6; 5 participants

Primary: Change in Hemoglobin (Hb) Level From Baseline to End of Treatment (EOT) — 14.58 g/L — p=<0.0001

Primary: Percentage of Participants With an Increase of Greater Than or Equal to 1 Gram Per Decilitre in Hemoglobin Level at Week 8 — 67.96 percentage of participants

Primary: Percentage of Participants With Response to Treatment Based on Hemoglobin Levels — 46.2 percentage of participants

Primary: Percentage of Participants With Early Treatment Response: Day 28 to 42 — 52.4; 56.5; 53.8 percentage of participants

Primary: Change in Hb Concentration — 0.48; 0.44 g/dL

Primary: Progression Free Survival — 7.4; 7.4 Months

Primary: Dose of Arsenic That Blocks Activation of p53 — 0.005 mg/kg

Primary: Percentage of Participants With Grade II-IV Acute Graft Versus Host Disease (GVHD) — 42; 38 percentage of participants

Primary: CR Rate — 42; 55; 134; 18 Participants

Primary: Disease Free Survival — 141; 135; 191; 560 Participants — p=0.0007

Primary: Haemoglobin Increase of Greater or Equal to 5g/l Following Receipt of Treatment — 53; 61 Participants

Primary: Patient Retention and Engagement With the MyChemoCare Application — 15; 12 Participants

Primary: Number of Red Blood Cell Transfusions Needed to Maintain Hemoglobin Levels (Short Term) — 2.3; 1.8 RBC Transfusions — p=<0.025

Primary: Overall Response Rate — 12; 1; 7 Participants

Primary: Number of Participants Experiencing Graft Failure — 1; 0; 0; 0 Participants

Primary: Rates of Durable Engraftment — 17.9; 15.75; 13; 18.25 days